Pulmocide Ltd.
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.pulmocide.com
Clinical Trials
16
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 123
- Registration Number
- NCT05238116
- Locations
- 🇺🇸
Clinical Research Site 029, Duarte, California, United States
🇺🇸Clinical Research Site 009, La Jolla, California, United States
🇺🇸Clinical Research Site 119, Sacramento, California, United States
A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)
- Conditions
- Pulmonary Aspergillosis
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 102
- Registration Number
- NCT05037851
- Locations
- 🇨🇦
Clinical Research Site, Toronto, Canada
🇺🇸Research Site, Saint Louis, Missouri, United States
🇺🇸Clinical Research Site 1, Houston, Texas, United States
The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.
- Conditions
- Lung Transplant InfectionAspergillosis
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 2
- Registration Number
- NCT03905447
- Locations
- 🇬🇧
Papworth Hospital, Papworth Everard, Cambridge, United Kingdom
🇬🇧Harefield Hospital, Harefield, Uxbridge, United Kingdom
🇬🇧Wythenshawe Hospital, Manchester, United Kingdom
The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 4
- Registration Number
- NCT03870841
- Locations
- 🇬🇧
Royal Brompton Hospital, London, United Kingdom
🇬🇧Northwest Lung Research Centre, Manchester, United Kingdom
The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases
- Conditions
- AsthmaRespiratory AspergillosisCOPDBronchiectasisRespiratory Candidiasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 13
- Registration Number
- NCT03745196
- Locations
- 🇬🇧
Glenfield Hospital, Leicester, United Kingdom
🇬🇧Royal Liverpool University Hospital, Liverpool, United Kingdom
🇬🇧Royal Brompton Hospital, London, United Kingdom
- Prev
- 1
- 2
- Next